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Amylinergic control of ingestive behavior
Abstract
Amylin controls nutrient fluxes by reducing food intake, slowing gastric emptying and reducing
postprandial glucagon secretion via a direct effect on the area postrema (AP). In the AP, amylin seems
to modulate the anorectic signal elicited by cholecystokinin (CCK). Amylin's excitatory action on AP
neurons and its anorectic effect may depend on diet composition because rats fed protein as exclusive
energy source showed a blunted response to amylin. In addition to a role in satiation (“episodic signal”),
recent studies suggest that amylin may also play a role as an adiposity (“tonic”) signal. Similar to leptin
or insulin, an elevated brain level of amylin resulted in lower body weight gain than in controls. This
may also in part be due to an increase in energy expenditure. Overall, amylin may be an interesting
target as a body weight lowering drug. Recent studies provided evidence that amylin, especially when
combined with insulin, leptin or PYY has long-term effects on food intake and body weight in humans. 
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Abstract 
Amylin controls nutrient fluxes by reducing food intake, slowing 
gastric emptying and reducing postprandial glucagon secretion via a 
direct effect on the area postrema (AP). In the AP, amylin seems to 
modulate the anorectic signal elicited by CCK. Amylin’s excitatory 
action on AP neurons and its anorectic effect may depend on diet 
composition because rats fed protein as exclusive energy source 
showed a blunted response to amylin. In addition to a role in satia-
tion (“episodic signal”), recent studies suggest that amylin may also 
play a role as an adiposity (“tonic”) signal. Similar to leptin or insu-
lin, an elevated brain level of amylin resulted in lower body weight 
gain than in controls. This may also in part be due to an increase in 
energy expenditure. Overall, amylin may be an interesting target as a 
body weight lowering drug. Recent studies provided evidence that 
amylin, especially when combined with insulin, leptin or PYY has 
long-term effects on food intake and body weight in humans.  
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Introduction 
Amylin is synthesized by the pancreatic B-cells and is co-secreted 
with insulin. In conjunction with insulin, amylin controls nutrient 
flux and the postprandial glucose concentration. E.g., amylin inhibits 
gastric acid secretion, gastric emptying, pancreatic glucagon secre-
tion, digestive enzyme secretion, and eating. The best investigated 
amylin function is its role as a hormonal control of meal ending sa-
tiation. Acute peripheral amylin reduces meal size. The effect is be-
haviorally specific. Unlike cholecystokinin (CCK), amylin may also 
act as an adiposity signal, such as leptin and insulin. Amylin’s basal 
blood concentration is correlated with the total amount of body fat. 
This information may be used as a feedback signal controlling en-
ergy homeostasis, i.e., food intake and energy expenditure.  
 
Physiological relevance of amylin as satiation signal  
Amylin meets most of the criteria for a physiological satiation signal 
in rats (Table 1; Lutz et al., 1995; Geary, 2004). First, food intake 
rapidly increases plasma amylin concentration within few minutes. 
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The magnitude of this increase is correlated with the amount eaten 
(Butler et al., 1990; Lutz et al., 1997). Second, all components of 
functional amylin receptors which consist of the calcitonin receptor 
(CT-R) as a core receptor and receptor-activity modifying proteins 
(RAMP 1 or RAMP 3), are present in the area postrema (AP) where 
amylin appears to act to inhibit eating (reviewed in Lutz, 2005; Lutz, 
2006). Third, low doses of exogenous amylin that yield plasma 
amylin levels only about two times higher than those measured 
postprandially, significantly inhibit eating (Pieber et al., 1994; Ar-
nelo et al., 1998; Reidelberger et al., 2004). Forth, as to hormone or 
receptor removal and replacement, indirect evidence is provided by 
the amylin knockout mouse, which shows the expected phenotype of 
overeating and increased adiposity (Devine and Young, 1998; Lutz, 
2005). Finally, peripheral or central amylin antagonists produce an 
effect opposite to that of amylin. E.g., when AC187 is administered 
into the AP, it blocks the anorectic effect of intraperitoneally in-
jected amylin and, when administered alone, stimulates eating by an 
increase in meal size (Mollet et al., 2004).  
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Mechanisms of amylin action.  
The AP lacks a functional blood brain barrier. Neurons in the AP 
with amylin receptors seem to play an essential role in peripheral 
amylin action. Amylin binding sites occur in high densities in the 
AP (Sexton et al., 1994) and amylin-sensitive AP neurons carry the 
CT-R (Becskei et al., 2004). Both RAMP1 and RAMP3 mRNA are 
also present in the mouse AP (Oliver et al., 2001; Ueda et al., 2001), 
and amylin-induced Fos mRNA and RAMP3 mRNA expression co-
localize in rat AP cells (Barth et al., 2004). Further, the anorectic ac-
tions of both acute and chronic peripheral amylin are eliminated in 
rats with lesions in the AP/NTS region (Lutz et al., 1998b; Lutz et 
al., 2001a). Lesions of vagal and non-vagal visceral afferents left 
amylin’s effect unaltered (Morley et al., 1994; Lutz et al., 1998a). 
Endogenous amylin released during meals also appears to act via AP 
amylin receptors because direct infusion of the amylin receptor an-
tagonist AC187 into the AP increased food intake (Mollet et al., 
2004). Further, peripheral exogenous amylin and endogenous amylin 
triggered by post-deprivation refeeding increased neuronal activa-
tion in the AP, characterized by the expression of Fos protein 
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(Riediger et al., 2001, 2002, 2004). Finally, in vitro studies showed 
that direct application of amylin onto AP neurons in brain slice 
preparations dose dependently increased the neuronal firing rate 
(Riediger et al., 2001, 2002).  
Whether more rostral amylin receptors also contribute to the anorec-
tic action of amylin, remains to be established. Amylin infusion into 
the third brain ventricle (i3vt) produces a potent and long-lasting re-
duction in feeding, and i3vt infusion of AC187 increases food intake 
and body weight in rats (Rushing et al., 2000a, 2001). 
 
Secondary to AP activation, peripheral amylin also elicits a positive 
Fos response in brain sites rostral to the AP, including the nucleus of 
the solitary tract (NTS), the lateral parabrachial nucleus (lPBN), and 
the central nucleus of the amygdala (CeNA) (Rowland et al., 1997; 
Rowland and Richmond, 1999; Riediger et al., 2004). None of these 
areas is activated by amylin in AP-lesioned animals. The AP, NTS, 
and the lPBN are necessary to convey amylin's anorectic signal to 
higher brain structures (Lutz et al., 1998b; Riediger et al., 2004; 
Becskei et al., 2007).  
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Interestingly, the same areas also seem to process other anorectic 
signals, such as CCK. However, at least partially different neuronal 
networks seem to mediate the effects of different peptides. CCK, but 
not amylin satiation involves the central serotoninergic system, 
while the dopaminergic and histaminergic systems contribute to 
amylin signaling (Lutz et al., 1996; Lutz et al., 2001b; Mollet et al., 
2001). 
 
The amylin-mediated Fos response in the AP is modulated by 
nutrients 
The AP as the necessary brain site to mediate peripheral amylin ac-
tion seems to be established. However, it was recently observed that 
at least at relatively low anorectic doses of amylin, the amylin-
induced c-Fos expression in the AP depended on the feeding status 
of rats. In other words, amylin produced a stronger c-Fos activation 
in rats that had been fasted prior to amylin administration than when 
fed ad libitum (Michel et al., 2007). The strong c-Fos response seen 
in fasted rats after low dose amylin was reproduced in rats fed a non-
caloric diet (cellulose-based non-caloric mash; NCM). Therefore, 
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direct gastro-intestinal signals like gastric distension, were unlikely 
to be the cause for the different amylin-induced c-Fos response in 
fasted versus ad libitum fed rats. Experiments using NCM 
supplemented with individual nutrients suggested that this difference 
may be linked to the amino acid content of the diet. Rats fed NCM 
supplemented with glucose or fat showed an amylin-induced c-Fos 
response in the AP that was similar to that seen in fasted rats or in 
rats fed unsupplemented NCM. In contrast, amylin produced only a 
weak c-Fos response in the AP when rats ate NCM supplemented 
with a casein-based protein source. This was consistent with 
behavioral experiments because amylin reduced eating in rats fed 
NCM or NCM supplemented with glucose or fat more than when 
supplemented with protein. We concluded that the anorectic potency 
of amylin may be attenuated by high protein diets. This effect may 
be overridden when the amount of carbohydrates/fat is high relative 
to the protein content, such as e.g. in standard chow because amylin 
effectively reduced chow intake despite a relatively low level of 
amylin-induced c-Fos expression in the AP under these conditions. 
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Hypothalamic involvement in amylin action 
Our previous studies suggested an involvement of the lateral 
hypothalamic area (LHA) in the anorectic action of amylin because 
the fasting induced neuronal activation in the LHA was specifically 
blocked by administration of an anorectic dose of amylin (Riediger 
et al., 2004). Further, amylin reduced the expression of orexigenic 
neuropeptides in the LHA, i.e. orexin and melanin-concentrating 
hormone (MCH; Barth et al., 2003). Interestingly, using double 
labeling immunohistochemistry we found that the neurons that are 
modulated by amylin express neither orexin A nor MCH (Soares 
Potes et al., 2007). Therefore, the phenotype of these neurons and 
the physiological relevance of the downregulation of MCH and 
orexin expression in LHA neurons by amylin (Barth et al., 2003) for 
amylin’s anorectic action remains unknown (Soares Potes et al., 
2007).  
 
Retrograde and anterograde tracing studies identified neuronal con-
nections between the brain areas affected by amylin (Soares Potes et 
al., 2007). Specifically, we confirmed that all brain areas that show 
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increased c-Fos expression after amylin (e.g., AP, NTS, lPBN, CeA) 
are connected. The majority of fiber projections to the LHA ap-
peared to originate from amylin-activated neurons in the lPBN. 
Therefore, we believe that the lPBN is a necessary relay between the 
AP/NTS region and the LHA for amylin effects. Only a small pro-
portion (about 10%) of amylin-activated neurons in the NTS stained 
positively for the tracer. Consistent with what was described above, 
fibers from amylin activated neurons in any of the mentioned brain 
areas did not seem to make contact with MCH or orexin expressing 
neurons in the LHA. Besides ascending projections within the AP-
lPBN axis, anterograde tracing also identified dense projections 
from amylin activated neurons in the lPBN to other hypothalamic 
areas, e.g., the ventromedial and paraventricular nuclei. The former 
projections are of particular interest because amylin’s anorectic ac-
tion depends on histaminergic transmission, possibly involving the 
ventromedial hypothalamic nucleus (Mollet et al., 2001, Mollet et 
al., 2003b). 
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Interactions of amylin with CCK and PYY. 
CCK and amylin interact in their control of eating. This may reflect 
a necessary part of CCK signaling because amylin antagonists at-
tenuated CCK’s anorectic action in rats (Lutz et al., 2000), and the 
anorectic effect of CCK was almost completely abolished in the ab-
sence of endogenous amylin (Mollet et al., 2003a). CCK’s effect 
could be rescued by a small, subthreshold dose of amylin (Mollet et 
al., 2003a). CCK signaling seems not to be required for amylin satia-
tion because CCK antagonists had no effect on amylin-induced sa-
tiation (Morley et al., 1994). 
While we have not yet tested combinations of amylin and PYY3-36 
in feeding experiments, we recently found that the effect of amylin 
to induce c-Fos expression in the AP was markedly enhanced by a 
dose of PYY3-36 that by itself had no effect on AP neurons as 
gauged by c-Fos expression (Riediger et al., 2007). This mechanism 
may be the neuronal correlate of the synergistic body weight lower-
ing effect of amylin and PYY3-36 (Roth et al., 2007). 
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Interactions of amylin with leptin and insulin.  
For several reasons, it seems plausible that amylin may interact with 
the adiposity signals leptin and insulin. First, amylin modulates 
CCK’s effect on eating (Lutz et al., 2000; Mollet et al., 2003a), and 
CCK’s anorectic action has been shown repeatedly to be modulated 
by adiposity signals (e.g., Riedy et al., 1995; Morton et al, 2005). 
Further, Eiden and colleagues had shown that amylin’s effect on 
eating is altered in animal models of defective leptin signaling. For 
example, leptin-deficient mice exhibited a markedly weaker 
anorectic response to the amylin agonist sCT than wildtype controls 
(Eiden et al., 2002). Finally both amylin’s and leptin’s anorectic 
effects depend on histaminergic signaling via H1 receptors (Mollet 
et al., 2001, 2003b). 
In fact, recent studies confirmed that leptin interacts with amylin to 
reduce food intake (Osto et al., 2007). Leptin injected centrally 
reduced eating in rats more when co-administered with peripheral 
amylin than either peptide alone. This was true for effective doses of 
leptin but also for a subthreshold leptin dose. This is consistent with 
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data showing that animals receiving a peripheral infusion of leptin 
plus amylin had a much larger decrease in body weight gain than 
rats receiving either hormone alone. Amylin restored responsiveness 
to leptin in diet-induced obesity (DIO)  rats which are leptin resistant 
(Mack et al., 2007).  
Similar to leptin, central insulin and peripheral amylin also interact 
to reduce food intake more than either peptide alone (Osto et al., 
2007). Consistent with this, subthreshold doses of peripheral insulin 
and amylin produced a significant anorectic effect when 
administered together (Rushing et al., 2000b).  
Collectively, these experiments demonstrate that central leptin and 
insulin may set the tone that determines amylin’s anorectic potency. 
Additional experiments suggested that a triple combination of 
amylin, leptin and PYY3-36 may further enhance the body weight 
lowering effect in rats.  
 
Even though both leptin and ghrelin seem to affect food intake via 
the same neuronal network in the hypothalamic arcuate nucleus, 
ghrelin and amylin do not seem to interact for their effect on food 
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intake (Osto et al., 2007). This is consistent with recently published 
data by Kobelt and colleagues (Kobelt et al., 2006). While ghrelin 
and CCK seem to interact (Kobelt et al., 2005), no such interaction 
between ghrelin and amylin was reported (Kobelt et al., 2006). 
Further, the response to amylin was unaltered in rats with markedly 
reduced biologically active circulating ghrelin. These rats had 
received a series of vaccinations against endogenous ghrelin. The 
induced antibodies bound virtually all ghrelin in the circulation and 
prevented ghrelin from entering the brain (Lutz, 2007). Collectively, 
these data indicate that ghrelin has no effect on the anorectic action 
of amylin. 
 
Amylin as an adiposity signal.  
 The control of eating results in relatively stable energy stores as 
adipose tissue. After body weight loss, there is a tendency to eat 
more and to restore body weight. Analogously, after weight gain, 
there is a tendency to reduce food intake and lose the gained weight. 
Adiposity signals are supposed to be implicated in this control sys-
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tem, and there is evidence to suggest that amylin may act as such a 
signal, similar to leptin and insulin. 
In that respect, CCK and amylin clearly seem to differ from each 
other. On chronic administration, CCK as a “classical satiating 
signal”, does not reduce body weight in rats because a sustained 
decrease in meal size is compensated by an increase in meal 
frequency (West et al., 1984). Chronic administration of amylin, 
however, reduces eating by a decrease in meal size without a 
compensatory increase in meal frequency. In fact, some studies 
reported a reduction in meal frequency. Body weight is lowered by 
chronic amylin administration (Arnelo et al., 1998; Rushing et al., 
2000a; Lutz et al., 2001a).  
 
Amylin provides information about the status of peripheral energy 
stores in the form of the adipose tissue mass because amylin is se-
creted in direct proportion to body fat mass (Pieber et al., 1994). 
Further, continuous peripheral infusion of amylin lowers body 
weight, and infusion of the amylin antagonist AC 187 has the oppo-
site effect (Lutz et al., 2001a; Reidelberger et al., 2004). Interesting-
18  
ly, chronic third ventricular (i3vt) infusion of amylin leads to consi-
derable weight loss due to a reduced fat mass after 10 days, while 
that of amylin’s antagonist AC 187 increases food intake and body 
fat mass without a concomitant increase in total body weight (Rush-
ing et al., 2001). Finally, amylin deficient knock-out mice have in-
creased body weight compared to controls. Hence, a sustained 
change in amylin signaling has profound effects on food intake, 
body weight, and body adiposity.  
Recent unpublished studies from our laboratory are consistent with 
the idea that amylin signals body adiposity to the brain. In one expe-
riment, based on a similar study with insulin by Chavez et al. (1995), 
rats were chronically infused centrally with amylin or saline via a 
i3vt cannula. Half of the rats were fasted for two days to lower start-
ing body weight. The important finding was that amylin-infused an-
imals, independent of prior manipulations, achieved exactly the 
same body weight. This body weight was significantly lower than in 
saline-infused control animals. This is consistent with the idea that 
the central amylin level is a signal to the brain that indicates the 
available energy stores. Increased amylin levels as e.g. in obesity 
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(Pieber et al., 1994), would trigger an appropriate counterregulatory 
response. It is currently unknown to what extent an effect of amylin 
on energy expenditure (Wielinga et al., 2007b) contributes to this re-
sponse. 
A follow-up study revealed a very interesting phenomenon. This 
study suggests that animals may develop “resistance” to chronic or 
acute amylin action under certain conditions. Rats were overfed by 
offering a calorie-rich diet (EnsureR) in addition to laboratory chow 
for 3 weeks. Control rats were fed chow ad libitum. After the over-
feeding period, amylin or saline were delivered i3vt. Rats appeared 
to be unresponsive to amylin after overfeeding with the calorie-rich 
diet because only chow-fed animals showed a marked decrease in 
body weight gain when infused with amylin. Interestingly, exposure 
of rats to EnsureR for 3 days only also resulted in a decreased effect 
of acute central amylin on eating. The underlying physiological 
mechanisms are as yet unknown. Further, it is unknown how the 
observed phenomenon of amylin resistance may relate to previous 
reports that amylin reduces food intake less effectively in obese 
animals of some obesity models. It is however important to note that 
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Eiden and colleagues (Eiden et al., 2002) had shown that higher 
doses of amylin are required to reduce eating in ob/ob mice, db/db 
mice and fa/fa rats. A similar phenomenon was observed in 
MC4Rko mice (Eiden et al., 2002) and in DIO rats. Collectively, 
these findings indicate that obese animals may respond less to a 
given dose of amylin. Because short-term exposure of rats to En-
sureR also made rats less sensitive to amylin, a direct diet-related ef-
fect, independent of body weight, may also play a role.  
 
Amylin’s effect on energy metabolism 
The amylin agonist sCT acutely increased energy expenditure in 
fasted rats. This was not related to altered physical activity or body 
temperature of the rats. Acute amylin administration had a similar 
effect but it was less pronounced than after sCT. This is most likely 
due to the shorter duration of action of amylin (Wielinga et al., 
2007b). Follow-up unpublished studies investigated the role of 
chronic amylin administration on energy expenditure. We showed 
that amylin prevented the decrease in energy expenditure that would 
normally be seen in animals that eat less (Wielinga et al., 2007a). 
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Preliminary evidence suggests that amylin’s effect on energy 
expenditure may also be mediated by the AP because low dose sCT 
infusion into the AP markedly increased energy expenditure. 
 
Amylin and obesity therapy in humans 
Several recent reports indicate that the amylin analogue pramlintide 
effectively reduces eating and body weight in humans (Hollander et 
al., 2004; Chapman et al., 2005). Hence, it is considered an interest-
ing treatment option for anti-obesity therapy. Type 2 diabetic over-
weight patients treated with a combination of insulin plus pramlin-
tide required less insulin and had a better glycemic control than 
insulin treated controls. Patients treated with insulin plus pramlintide 
also lost body weight while insulin treated controls did not. Using 
the combination therapy, body weight was decreased most in severe-
ly obese patients with a body mass index >40 (Hollander et al., 
2004). Further, acute pramlintide treatment decreased the size of test 
meals by about 20% in both type 2 diabetics and nondiabetic obese 
individuals (Chapman et al., 2005). Normal perceptions of fullness 
were undisturbed and side effects were minor. Pramlintide produced 
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nausea in some but not all studies (Hollander et al., 2004; Chapman 
et al., 2005), but this effect was usually transient (i.e., <4 weeks) and 
mild.  
Chapman et al. (2007) extended their studies and showed that acute 
pramlintide administration prior to a standardized pre-meal reduced 
ad libitum eating in healthy normal weight men during a subsequent 
buffet meal. Despite reduced caloric intake and reduced meal dura-
tion, similar hunger and fullness feelings were reported after the 
buffet meal. Another report produced consistent results in that 24-
week pramlintide treatment of obese subjects resulted in reduced 
body weight due to a reduction in daily food intake and portion sizes 
(Smith et al., 2007). Further, pramlintide also seemed to improve the 
perceived control of eating because less binge eating episodes were 
reported. 
Based on promising rodent data that the coadministration of amylin 
and leptin produced stronger eating inhibitory effects than either 
hormone alone (Osto et al., 2007), Roth et al. (2008a) recently pub-
lished data on a 24-week study in overweight and obese individuals. 
They convincingly showed that the coadministration of leptin plus 
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amylin produced body weight loss that was significantly more pro-
nounced than by either peptide alone. Parallel rodent experiments 
showed that amylin may restore leptin effectiveness in overweight 
individuals, possibly by upregulating the leptin-induced pSTAT3 
expression in specific hypothalamic nuclei (Roth et al., 2008a). The 
latter is consistent with our own unpublished data that acute amylin 
administration increased leptin receptor expression in the hypotha-
lamus. Even though the underlying mechanisms seem largely un-
known, it may be interesting to note that amylin may also produce 
additive anorectic and body weight lowering effects when combined 
with other anti-obesity drugs, e.g. sibutramine (Roth et al., 2008b). 
Overall, these data indicate that the amylin analogue pramlintide is a 
new promising anti-obesity therapy both for overweight type 2 di-
abetics and for overweight non-diabetics. 
 
Summary, conclusions and future perspectives  
Blood-borne amylin reduces meal size by stimulating neurons in the 
AP.  Besides enhancing the action of other satiating signals at the 
level of the hindbrain, amylin interacts with signals controlling 
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energy homeostasis such as leptin and insulin, possibly at the level 
of the hypothalamus and the hindbrain.  Finally, there is evidence 
that amylin itself functions as an adiposity signal in addition to a sat-
iation signal. 
Future studies will concentrate on the brain’s sensitivity to the ano-
rectic and body weight lowering effects of amylin under various ex-
perimental conditions. This will follow up on findings that amylin 
sensitivity may be affected by specific dietary conditions. These stu-
dies will be conducted in the frame of ongoing efforts to elucidate 
the mechanisms of amylin action in the central nervous system. 
Another focus will be on the usefulness of amylin for clinical thera-
py. Numerous studies have proven the effectiveness of amylin and 
its analogues in reducing eating and body weight in humans. Espe-
cially the combination therapy of amylin plus leptin produced effects 
on eating and body weight that went far beyond those of the individ-
ual hormones. This combination therapy bears interesting clinical 
potential for the treatment of human obesity. 
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Table 1 
Criteria for the physiological action of hormonal controls of eating 
(Geary, 2004) 
---------------------------------------------------------------------------------- 
(1) Secretion   Secretion of the hormone is changed  
    by eating. 
(2) Receptor   Receptors are present at the site of ac 
    tion. 
(3) Physiological dose Mimicking the secretion pattern of the 
endogenous hormone by the exogen-
ous hormone reproduces the eating ef-
fect. 
(4) Removal, replacement The eating effect is prevented by re-
moval of the hormone or the critical 
receptors. Hormone replacement or re-
ceptor rescue reproduces the effect. 
(5) Antagonism  The eating effect of the endogenous  
    hormone is prevented by antagonizing  
    hormone signaling. This also prevents  
    the eating effect of physiological doses  
    of the exogenous hormone. 
---------------------------------------------------------------------------------- 
 
